- Antibodies, Monoclonal
- Accession Number
Antibodies produced by a single clone of cells.
- ATC Classification
Drug Drug Description Cetuximab An endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck. Trastuzumab A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Rituximab A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. Pertuzumab An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. Obinutuzumab An antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil. Pembrolizumab A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma. Gemtuzumab ozogamicin A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. Palivizumab A monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. Omalizumab A monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria. Adalimumab A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Infliximab A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Muromonab A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients. Alemtuzumab A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis. Natalizumab A monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. Daclizumab A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. Eculizumab A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Ranibizumab A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Pexelizumab For the treatment of inflammation during cardiac surgery. Epratuzumab Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus. Labetuzumab Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab" Matuzumab Investigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer. Fontolizumab Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders. Otelixizumab Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders. Enokizumab Investigated for use/treatment in asthma. Farletuzumab Investigated for use/treatment in ovarian cancer. Veltuzumab Investigated for use/treatment in lymphoma (non-hodgkin's). Ustekinumab A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. TNX-901 Investigated for use/treatment in allergic reaction. Inotuzumab ozogamicin An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). RI 624 Investigated for use/treatment in pain (acute or chronic). Eldelumab Investigated for use/treatment in ulcerative colitis. Leronlimab A humanized monoclonal antibody being investigated Nimotuzumab Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer. Tocilizumab An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). Motavizumab Investigated for use/treatment in viral infection and pediatric indications. Elotuzumab An antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents. AVE9633 Investigated for use/treatment in leukemia (myeloid). XmAb 2513 Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's). Coltuximab ravtansine Investigated for use/treatment in lymphoma (non-hodgkin's). Lucatumumab Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified). Siplizumab Investigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified). Apolizumab Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors. Sibrotuzumab Investigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer. Bivatuzumab Investigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer. Reslizumab An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults. Teplizumab Investigated for use/treatment in diabetes mellitus type 1. Mepolizumab An IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults. Denosumab A RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures. Belimumab A B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus. Certolizumab pegol A tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Vedolizumab An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators. Idarucizumab An antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran. Ixekizumab A monoclonal antibody used to treat moderate to severe plaque psoriasis. Bapineuzumab Bapineuzumab has been investigated for the treatment of Alzheimer's Disease. Solanezumab Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial. Sarilumab A monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs. Emibetuzumab Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. Ligelizumab Ligelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others. Landogrozumab Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer. Ocrelizumab A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. Visilizumab Visilizumab has been investigated for the treatment of Ulcerative Colitis. Gevokizumab Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine... Etrolizumab Etrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis. Etaracizumab Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer. Aducanumab Aducanumab has been used in trials studying the treatment of Alzheimer's Disease. Tanezumab Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic. Bococizumab Bococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. Mirvetuximab Soravtansine Mirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others. Mogamulizumab A monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy. Inebilizumab A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD). Blosozumab Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal. Dacetuzumab Investigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma. Tovetumab Tovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies. Demcizumab Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. Abituzumab Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic. Concizumab Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder. Depatuxizumab Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors. Rontalizumab Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus. Clazakizumab Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis. Ozanezumab Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. Sacituzumab govitecan Sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.[L13002] Milatuzumab Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others. Olokizumab Olokizumab has been used in trials studying the treatment of Crohn's Disease. Emicizumab An antibody against Factor IXa and Factor X used to treat hemophilia A. Sulesomab Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes. Besilesomab A monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis. Panitumumab A recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. Ramucirumab An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply. Ipilimumab A human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Catumaxomab For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. Ofatumumab An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. Brentuximab vedotin A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Nivolumab A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma. Blinatumomab An antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Dinutuximab An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Necitumumab A monoclonal antibody used to treat metastatic squamous non-small cell lung cancer. Edrecolomab Not Annotated Depatuxizumab mafodotin No approved indication. Golimumab A TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Efalizumab A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Alirocumab A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C). Evolocumab A PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. Daratumumab A CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma. Atezolizumab A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy. Brodalumab A monoclonal antibody used to treat moderate to severe plaque psoriasis. Avelumab A monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma. Durvalumab An antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer. Dupilumab A monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults. Lanadelumab A plasma kallikrein inhibitor used to treat attacks of hereditary angioedema. Galcanezumab A calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches. Benralizumab A monoclonal antibody used to treat eosinophilic asthma. Emapalumab An interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis. Ravulizumab A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria. Olaratumab A platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS). Risankizumab An interleukin-23 antagonist used to treat moderate to severe plaque psoriasis. Isatuximab A chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies. Lintuzumab Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia). Bevacizumab zirconium Zr-89 Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors). Refanezumab Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients). Pateclizumab Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in... Tigatuzumab Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)). Ponezumab Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease). GMA-161 GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)). Pinatuzumab vedotin Pinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With... Naratuximab emtansine Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia). Bermekimab Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis). Burosumab A fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia. Abciximab A monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention. Basiliximab A monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients. Vadastuximab Talirine Vadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia. Simtuzumab Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis. Fasinumab Fasinumab has been used in trials studying the basic science and treatment of Sciatica, Back Pain, Low Back Pain, Osteoarthritis, Hip, and Abdominal Pain Upper, among others. Labetuzumab govitecan Labetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer. Lumretuzumab Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer. Ecromeximab Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma. Bimekizumab Bimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis. Rovalpituzumab Tesirine Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others. Tregalizumab Tregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis. Erenumab A calcitonin-gene related peptide antagonist used to prevent migraines. Eptinezumab A monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults. Lecanemab Lecanemab is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease. Camrelizumab Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy). Gancotamab Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients). Codrituzumab Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma). Brolucizumab An anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration. Rozanolixizumab Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy). Trastuzumab deruxtecan An antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer. Tafasitamab A CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies. Nemolizumab Nemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)). Crizanlizumab A monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease. Enfortumab vedotin An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. Teprotumumab A fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease. Fremanezumab A humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines. Theralizumab Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia... Belantamab mafodotin An anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Cemiplimab A programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma. Satralizumab A subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
- Drugs & Drug Targets